Paul Silva Net Worth

The estimated Net Worth of Paul M Silva is at least 25.9 百万$ dollars as of 26 February 2021. Mr. Silva owns over 2,782 units of Vertex Pharmaceuticals stock worth over 4,692,330$ and over the last 16 years he sold VRTX stock worth over 18,006,964$. In addition, he makes 3,197,860$ as Senior Vice President、 Controller at Vertex Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Silva VRTX stock SEC Form 4 insiders trading

Paul has made over 104 trades of the Vertex Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently he sold 2,782 units of VRTX stock worth 588,254$ on 26 February 2021.

The largest trade he's ever made was exercising 56,295 units of Vertex Pharmaceuticals stock on 9 May 2012 worth over 1,938,237$. On average, Paul trades about 2,828 units every 33 days since 2008. As of 26 February 2021 he still owns at least 9,884 units of Vertex Pharmaceuticals stock.

You can see the complete history of Mr. Silva stock trades at the bottom of the page.

Paul Silva biography

Paul M. Silva is Senior Vice President, Controller of the company, and he is no longer as Interim Chief Financial Officer, Effective April 10, 2019. Mr. Silva is our Senior Vice President and Corporate Controller, a position he has held since April 2011. Mr. Silva joined us in August 2007 as Senior Director, Accounting Operations and was our Vice President and Corporate Controller from September 2008 through April 2011. Prior to joining us, he was the Vice President, Internal Reporting at Iron Mountain Incorporated from July 2006 until August 2007 and a consultant to Iron Mountain’s financing department from April 2005 until July 2006. He was the Finance Director of the Bioscience Technologies Division of Thermo Electron Corporation from 2002 to April 2005. Mr. Silva holds a B.S. in accounting from Assumption College.

What is the salary of Paul Silva?

As the Senior Vice President、 Controller of Vertex Pharmaceuticals, the total compensation of Paul Silva at Vertex Pharmaceuticals is 3,197,860$. There are 8 executives at Vertex Pharmaceuticals getting paid more, with Jeffrey Leiden having the highest compensation of 18,790,000$.

How old is Paul Silva?

Paul Silva is 52, he's been the Senior Vice President、 Controller of Vertex Pharmaceuticals since 2019. There are 16 older and 8 younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals, Inc. is William Young, 75, who is the Independent Director.

What's Paul Silva's mailing address?

Paul's mailing address filed with the SEC is C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA, 94158.

Insiders trading at Vertex Pharmaceuticals

Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over 934,925,905$ worth of Vertex Pharmaceuticals stock and bought 308,652 units worth 12,298,449$ . The most active insiders traders include Lloyd Carney、Jeffrey M Leiden、Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of 4,747,875$. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth 1,888,216$.

What does Vertex Pharmaceuticals do?

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.

Complete history of Mr. Silva stock trades at Vertex Pharmaceuticals、Nurix Therapeutics

Vertex Pharmaceuticals executives and stock owners

Vertex Pharmaceuticals executives and other stock owners filed with the SEC include:

• Jeffrey Leiden,
  Executive Chairman of the Board
• Stuart Arbuckle,
  Executive Vice President, Chief Commercial Officer
• Reshma Kewalramani,
  President, Chief Executive Officer, Director
• Amit Sachdev,
  Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
• David Altshuler,
  Executive Vice President - Global Research, Chief Scientific Officer
• Michael Parini,
  Executive Vice President, Chief Legal and Administrative Officer
• Dr. Reshma Kewalramani FASN, M.D.,
  CEO, Pres & Director
• Charles Wagner,
  Chief Financial Officer, Executive Vice President
• Paul Silva,
  Senior Vice President, Controller
• Dr. Jeffrey Marc Leiden M.D., Ph.D.,
  Exec. Chairman
• Stuart A. Arbuckle B.Sc.,
  Exec. VP & COO
• Dr. David M. Altshuler,
  Exec. VP of Global Research & Chief Scientific Officer
• Charles F. Wagner Jr.,
  Exec. VP & CFO
• Bruce Sachs,
  Co-Lead Independent Director
• Margaret McGlynn,
  Independent Director
• Terrence Kearney,
  Independent Director
• Sangeeta Bhatia,
  Independent Director
• Yuchun Lee,
  Independent Director
• William Young,
  Independent Director
• Alan Garber,
  Independent Director
• lloyd Carney,
  Independent Director
• Michael Partridge,
  Vice President - Investor Relations
• Diana McKenzie,
  Independent Director
• Nia Tatsis,
  Senior Vice President, Chief Regulatory Officer
• John Gray,
  Senior Vice President, Genetic Therapies
• Gerald Bruce,
  Executive Vice President, Commercial Operations
• Carmen Bozic,
  Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
• Joy Liu,
  Sr. VP & Gen. Counsel
• Damian W. Wilmot Esq.,
  Sr. VP, Chief Risk and Compliance Officer
• Mike Tirozzi,
  SVP and Chief Information & Data Officer
• Kristen Ambrose,
  Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services
• Joshua S Boger,
  Chairman & CEO
• Elaine Ullian,
  Director
• Ian F Smith,
  SVP & CFO
• Jeffrey Chodakewitz,
  SVP GMDA, CMO
• Thomas Graney,
  Chief Financial Officer
• Michel Lagarde,
  Director
• Wayne Joseph Riley,
  Director
• Peter Mueller,
  CSO & SVP Drug Discovery
• Thomas Connolly,
  SVP, Human Resources
• Kenneth L Horton,
  EVP & Chief Legal Officer
• Megan E Pace,
  SVP, Corp. Communications
• Christiana Stamoulis,
  SVP, Corp Strategy & Bus Devlp
• Matthew Emmens,
  Director
• Lisa Kelly,
  SVP, Human Resources
• Dennis L Winger,
  Director
• Eugene Cordes,
  Director
• Nancy Wysenski,
  EVP & Chief Commercial Officer
• David T Howton,
  SVP
• Kenneth S Boger,
  SVP & General Counsel
• Kurt Graves,
  EVP, Chief Commercial Officer
• John J Alam,
  SVP, Drug Eval. & Appr.
• Stuart J Collinson,
  Director
• Charles A Sanders,
  Director
• Roger W Brimblecombe,
  Director
• Freda C Lewis Hall,
  EVP, Medicines Development
• Eve Elizabeth Slater,
  Director
• Richard C Garrison,
  SVP, Organizational Developmen
• Johanna Messina Power,
  Controller
• Victor A Hartmann,
  EVP, Strategic & Corp. Devlp.
• Eric Brandt,
  Director
• Lynne H Brum,
  VP, Corp. Comm.&Financial Plan
• Paul A Negulescu,
  VP, Research
• John F Niblack,
  Director
• Iain P M Buchanan,
  VP, European Operations
• Vicki L Sato,
  President
• N Anthony Coles,
  SVP, Comm. Ops.
• Bastiano Sanna,
  EVP, Cell & Genetic Therapies
• Joy Liu,
  SVP, General Counsel
• Kristen Ambrose,
  SVP & Chief Accounting Officer
• Suketu Upadhyay,
  Director
• Jonathan Biller,
  EVP and Chief Legal Officer
• Nancy Thornberry,
  Director
• Edward Morrow Iii Atkinson,
  EVP, Chief Technical Ops. Off.
• Jennifer Schneider,
  Director